DoD awards $32.8M for COVID-19 test kits, highlighting rapid response needs during the pandemic

Contract Overview

Contract Amount: $32,824,500 ($32.8M)

Contractor: Abbott Rapid DX North America LLC

Awarding Agency: Department of Defense

Start Date: 2020-09-29

End Date: 2020-10-06

Contract Duration: 7 days

Daily Burn Rate: $4.7M/day

Competition Type: NOT COMPETED

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 8507687406!BINAXNOW COVID-19 AG CARD 40C

Place of Performance

Location: ORLANDO, ORANGE County, FLORIDA, 32810

State: Florida Government Spending

Plain-Language Summary

Department of Defense obligated $32.8 million to ABBOTT RAPID DX NORTH AMERICA LLC for work described as: 8507687406!BINAXNOW COVID-19 AG CARD 40C Key points: 1. Contract awarded for essential COVID-19 diagnostic supplies, crucial for public health response. 2. Sole-source award indicates urgent need or limited availability of specific testing solutions. 3. Short contract duration suggests immediate deployment requirements. 4. High value for a short-term delivery order points to significant demand. 5. Focus on in-vitro diagnostics aligns with critical public health infrastructure. 6. Geographic focus on Florida for delivery may indicate regional testing initiatives.

Value Assessment

Rating: fair

The contract value of $32.8 million for a 7-day delivery period is substantial, suggesting a high per-unit cost or a very large quantity of test kits. Without specific unit counts or comparable sole-source awards for similar rapid diagnostic tests during the early pandemic, a precise value-for-money assessment is difficult. However, the urgency and nature of the pandemic likely influenced pricing, potentially leading to higher costs than under normal competitive conditions. The fixed-price nature provides some cost certainty.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, likely due to the urgent and critical need for COVID-19 testing supplies at the onset of the pandemic. The 'NOT COMPETED' status indicates that a full and open competition was not feasible or practical given the circumstances. While this ensures rapid acquisition, it limits the opportunity for price discovery through competitive bidding and may result in higher costs for the government.

Taxpayer Impact: Sole-source awards mean taxpayers did not benefit from competitive pricing, potentially leading to a higher overall expenditure for these essential supplies.

Public Impact

Beneficiaries include military personnel and potentially civilian populations served by DoD facilities requiring rapid COVID-19 testing. Services delivered include the provision of BinaxNow COVID-19 Ag Card tests. Geographic impact is centered on Florida, where the delivery orders were fulfilled. Workforce implications are minimal for this specific contract, focusing on supply chain and logistics rather than direct service provision.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price competition, potentially increasing costs for taxpayers.
Short duration and high value may indicate premium pricing due to urgent need.
Lack of competition makes it difficult to benchmark against market rates for similar products.

Positive Signals

Contract addresses a critical public health need during a national emergency.
Rapid delivery ensures availability of essential diagnostic tools.
Fixed-price contract provides cost certainty for the awarded amount.

Sector Analysis

The healthcare sector, specifically the segment focused on diagnostic testing and medical supplies, is characterized by rapid innovation and high demand, especially during public health crises. The market for COVID-19 testing evolved quickly, with initial shortages and high prices giving way to increased production and competition over time. This contract falls within the 'In-Vitro Diagnostic Substance Manufacturing' category, a critical component of the broader healthcare supply chain. Comparable spending benchmarks are difficult to establish due to the unique market conditions of the early pandemic.

Small Business Impact

This contract was not awarded to small businesses, nor does it appear to have specific small business set-aside provisions. The sole-source nature and the focus on a large, established manufacturer like Abbott suggest that subcontracting opportunities for small businesses within this specific award are unlikely. The broader impact on the small business ecosystem would depend on whether Abbott's own supply chain involves small businesses, which is not detailed here.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Defense's contracting and financial management regulations. The Defense Contract Management Agency (DCMA) would likely be involved in monitoring delivery and compliance. Transparency is limited due to the sole-source nature. Inspector General jurisdiction would apply if any fraud, waste, or abuse were suspected.

Related Government Programs

COVID-19 Testing Supplies
Public Health Emergency Response
Diagnostic Test Kits
Department of Defense Medical Procurement
Emergency Supply Chain Management

Risk Flags

Sole-source award
Urgent need procurement
Potential for inflated pricing due to market conditions
Limited transparency in competition

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $32.8 million to ABBOTT RAPID DX NORTH AMERICA LLC. 8507687406!BINAXNOW COVID-19 AG CARD 40C

Who is the contractor on this award?

The obligated recipient is ABBOTT RAPID DX NORTH AMERICA LLC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Logistics Agency).

What is the total obligated amount?

The obligated amount is $32.8 million.

What is the period of performance?

Start: 2020-09-29. End: 2020-10-06.

What was the specific justification for awarding this contract on a sole-source basis?

The justification for a sole-source award typically stems from urgent and compelling circumstances where a delay in award would cause serious injury to the government. In the context of the COVID-19 pandemic's early stages, the critical need for rapid diagnostic testing to control the spread, protect personnel, and maintain operational readiness likely necessitated an immediate acquisition. This often means that only one responsible source could meet the government's needs in the required timeframe, or that the government could not identify other sources capable of fulfilling the requirement quickly enough through a competitive process.

How does the per-unit cost of these test kits compare to market rates at the time of award?

Determining the precise per-unit cost and comparing it to market rates is challenging without the exact quantity of test kits procured under this $32.8 million contract. However, during the initial phases of the pandemic, demand for COVID-19 tests far outstripped supply, leading to significantly inflated prices across the market. Sole-source awards, by their nature, bypass competitive bidding, which is the primary mechanism for achieving favorable market rates. Therefore, it is probable that the per-unit cost was higher than what might have been achieved through a competitive process, reflecting both the urgency and the prevailing market conditions.

What were the risks associated with awarding a sole-source contract for essential medical supplies?

The primary risks associated with sole-source contracting for essential medical supplies include potential overpayment due to lack of price competition, limited assurance of best value, and the possibility of supply chain vulnerabilities if the sole source faces production issues. For taxpayers, the risk is a higher expenditure than necessary. From a public health perspective, reliance on a single source could create bottlenecks if that source cannot meet demand or experiences disruptions. However, in emergency situations, the risk of not having critical supplies immediately available often outweighs the financial risks of sole-source procurement.

What is the track record of Abbott Rapid Dx North America LLC in supplying diagnostic tests to the federal government?

Abbott Laboratories, including its rapid diagnostics division, has a significant history of supplying medical and diagnostic products to various U.S. government agencies, including the Department of Defense and the Department of Health and Human Services. They are a major player in the diagnostics market, known for developing and manufacturing a range of tests. Their ability to scale production rapidly was critical during the pandemic, and they have been a key supplier of COVID-19 testing solutions to both government and commercial markets. Past performance data would be available through federal procurement databases.

How did this contract contribute to the overall federal response to the COVID-19 pandemic?

This $32.8 million contract played a direct role in bolstering the federal government's capacity to test for COVID-19, particularly within the Department of Defense's sphere of operations and potentially extending to related civilian support. By securing a substantial quantity of BinaxNow rapid antigen tests, the DoD aimed to ensure the health and readiness of its personnel and mitigate the spread of the virus. Such awards were crucial components of the broader federal strategy to increase testing availability, enable faster decision-making, and manage the public health crisis.

What is the significance of the short contract duration (7 days)?

The extremely short contract duration of just 7 days for delivery indicates an immediate and critical need for the BinaxNow COVID-19 Ag Card tests. This suggests that the procurement was intended to address an urgent gap in supply or to meet an immediate operational requirement, such as supporting a specific deployment, event, or outbreak response within the DoD. It highlights the dynamic and often reactive nature of federal procurement during a rapidly evolving public health emergency, where rapid deployment of resources was paramount.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Abbott Laboratories

Address: 30 S KELLER RD STE 100, ORLANDO, FL, 32810

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $32,824,500

Exercised Options: $32,824,500

Current Obligation: $32,824,500

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: SPE2DE20D0027

IDV Type: IDC

Timeline